Latest Administration News

Page 8 of 164
Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.
Ada Torres
Ada Torres
27 Feb 2026
Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.
Ada Torres
Ada Torres
27 Feb 2026
Strata Investment Holdings plc reported a striking £6.16 million comprehensive profit for 2025, propelled by robust investment portfolio returns and a significant revaluation uplift in its copper royalty assets. Despite operational delays from adverse weather, the company’s strategic focus on high-conviction resource investments and royalties positions it well amid evolving commodity markets.
Maxwell Dee
Maxwell Dee
27 Feb 2026
Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.
Ada Torres
Ada Torres
27 Feb 2026
NobleOak Life Limited reported a robust half-year performance with underlying net profit after tax rising 11% to $9.6 million, driven by strong premium growth and market share gains. However, statutory profit fell 23% due to one-off costs and provisions, prompting a pause on dividends amid strategic transitions.
Victor Sage
Victor Sage
27 Feb 2026
ARC Funds Limited posted a $1 million loss for the half-year ending December 2025, while significantly increasing revenues and expanding its ownership in The Term Deposit Shop to 74.48%. The company raised nearly $1.9 million to support growth initiatives amid ongoing operational challenges.
Claire Turing
Claire Turing
27 Feb 2026
Channel Infrastructure reported steady FY25 financials with record throughput and key project progress, while raising dividends and expanding into Australia via a strategic pipeline stake.
Victor Sage
Victor Sage
27 Feb 2026
Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.
Ada Torres
Ada Torres
26 Feb 2026
Dubber Corporation reported a 9% revenue decline to $18.7 million for the half-year ending December 2025, alongside a 65% reduction in net loss. The company pursues growth through AI innovation and cost efficiencies while navigating ongoing legal proceedings.
Sophie Babbage
Sophie Babbage
26 Feb 2026
Neurizon Therapeutics has commenced dosing in a major Phase 2/3 trial of its lead drug NUZ-001 for ALS, marking a critical step in advancing treatment options for this devastating disease.
Ada Torres
Ada Torres
26 Feb 2026
Australian Ethical Investment Limited has reported a robust half-year performance, with profits and funds under management hitting new highs, underpinned by strategic platform upgrades and sustained net inflows.
Claire Turing
Claire Turing
26 Feb 2026
Firebird Metals has locked in exclusive global rights to five critical LMFP patents, solidifying its position in the lithium-ion battery materials market and paving the way for its Australian Demonstration Plant.
Maxwell Dee
Maxwell Dee
26 Feb 2026